HCA Healthcare, Inc.
$138.89B- Market cap
- $93.44B
- Debt
- +$46.49B
- Cash
- −$1.04B
Capital structure 67% equity / 33% debt · EV / Revenue 1.84x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: HCA stock price at discount vs A $421.21 current versus $887.22 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at A's multiple
Implied fair value · at HCA's multiple
Snapshot Sep 10, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Multiple discount
Lower P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 67% equity / 33% debt · EV / Revenue 1.84x
Capital structure 92% equity / 8% debt · EV / Revenue 6.03x · EV proxy / EBITDA proxy 23.72x
HCA carries the larger enterprise value at $138.89B against $41.91B; HCA trades on the lower EV / Revenue multiple (1.84x vs 6.03x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
HCA Healthcare, Inc. · implied price per share
Bear
$171.11
Base
$241.68
Bull
$336.89
AGILENT TECHNOLOGIES, INC. · implied price per share
Bear
$47.37
Base
$57.73
Bull
$71.70
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LABCORP HOLDINGS INC.
HCA vs LH
WEST PHARMACEUTICAL SERVICES INC
HCA vs WST
BAXTER INTERNATIONAL INC
HCA vs BAX
MCKESSON CORP
HCA vs MCK
Cigna Group
HCA vs CI
UNITEDHEALTH GROUP INC
HCA vs UNH
THERMO FISHER SCIENTIFIC INC.
HCA vs TMO
ILLUMINA, INC.
HCA vs ILMN
BIO-TECHNE Corp
HCA vs TECH
BRUKER CORP
HCA vs BRKR
Azenta, Inc.
HCA vs AZTA
WATERS CORP /DE/
HCA vs WAT
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe HCA can maintain revenue growth above A while preserving current margins and eventually rerating closer to its DCF or historical range, then HCA looks attractive to buy because it trades at 14.2x P/E and 1.2x P/S versus A's 30.3x and 5.6x.
HCA trades at a steep valuation discount to A across P/E, P/S, EV/EBITDA, and EV/Revenue, suggesting the market is paying much more for A's profitability and quality profile. The current price also sits near the lower end of HCA's historical band and below both A-implied range and DCF range.
Supporting Metrics